Favorable outcomes found for patients
with papillary thyroid cancer that has not metastasized regardless of treatment
Individuals with papillary thyroid cancer that has not
spread beyond the thyroid gland appear to have favorable outcomes regardless of
whether they receive treatment within the first year after diagnosis, according
to a report in the May issue of Archives of Otolaryngology-Head & Neck Surgery,
one of the JAMA/Archives journals.
Papillary thyroid cancer is commonly found on autopsy
among individuals who died of other causes, according to background information
in the article. "Studies published as early as 1947 demonstrated it, and more
recently, a report has shown that nearly every thyroid gland might be found to
have a cancer if examined closely enough," the authors write. "The advent of ultrasonography
and fine-needle aspiration biopsy has allowed many previously undetected cancers
to be identified, changing the epidemiology of the disease. Over the past 30 years,
the detected incidence of thyroid cancer has increased three-fold, the entire
increase attributable to papillary thyroid cancer and 87% of the increase attributable
to tumors measuring less than 2 centimeters."
Louise Davies, M.D., M.S., of Dartmouth Medical School,
Hanover, N.H. and Gilbert Welch, M.D., M.P.H., both also of Department of Veterans
Affairs Medical Center, White River Junction, Vt., and The Dartmouth Institute
for Health Policy and Clinical Practice, Hanover, studied cancer cases and individual
treatment data from National Cancer Institute registries. They then tracked cause
of death through the National Vital Statistics System.
The researchers identified 35,663 patients with papillary
thyroid cancer that had not spread to the lymph nodes or other areas at diagnosis.
Of these, 440 (1.2 percent) did not undergo immediate, definitive treatment. Over
an average of six years of follow-up, six of these patients died of their cancer.
This was not significantly different from the rate of cancer death among the 35,223
individuals who did undergo treatment (161 over an average of 7.6 years of follow-up).
The 20-year survival rate from cancer was estimated to
be 97 percent for those who did not receive treatment and 99 percent for those
who did. "These data help put management decisions about localized papillary thyroid
cancer in perspective: papillary thyroid cancers of any size that are confined
to the thyroid gland, have no lymph node metastases at presentation and do not
show extraglandular extension are unlikely to result in death due to the cancer,"
the authors write.
"Thus, clinicians and patients should feel comfortable
considering the option to observe for a year or longer cancers that fall into
this category," they conclude. "When treatment is elected, the cancers in this
category can be managed with either hemithyroidectomy or total thyroidectomy,
and the prognosis will be the same."
This study was supported in part by a Research Enhancement
Award from the Department of Veterans Affairs and the Robert Wood Johnson Faculty
Scholars Program. Please see the article for additional information, including
other authors, author contributions and affiliations, financial disclosures, funding
and support, etc.
|